The clinical landscape of CAR NK cells. [PDF]
Exp Hematol OncolAbstract Chimeric antigen receptor (CAR) NK cell therapy has emerged as a promising alternative to CAR T cell therapy, offering significant advantages in terms of safety and versatility. Here we explore the current clinical landscape of CAR NK cells, and their application in hematologic malignancies and solid cancers, as well as their ...
Jørgensen LV +3 more
europepmc +4 more sources
CAR-NK cells: A promising cellular immunotherapy for cancer [PDF]
EBioMedicine, 2020 Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating ...
Guozhu Xie +5 more
doaj +5 more sources
Single VHH-directed BCMA CAR-NK cells for multiple myeloma
Experimental Hematology & Oncology, 2023 Natural killer (NK) cells are promising alternatives for the production of “off-the-shelf” CAR products, posing a lower risk of cytokine release syndrome (CRS) than CAR-T cells.
Quan Ren +7 more
doaj +3 more sources
Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells [PDF]
Molecular Therapy: OncologyNatural killer (NK) cells have the intrinsic ability to kill cancer cells and are thus targeted in immunotherapy. Anti-CD19 CAR NK cells have shown efficacy in clinical studies in treating B cell malignancies; however, the full cytotoxic capacities of ...
Juliane Mietz +11 more
doaj +2 more sources
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy [PDF]
Experimental Hematology & OncologyChimeric antigen receptor (CAR)-NK therapy holds great potential for tumor treatment, but current CAR designs are primarily optimized for T cells, raising concerns about their suitability for NK cells. This study compared two dominant CAR designs used in
Pengchao Zhang +8 more
doaj +2 more sources
Soluble factors released by peripheral blood-derived CAR-NK cells cause bystander myeloid cell activation [PDF]
Frontiers in ImmunologyIntroductionCAR-T cell therapy is associated with life-threatening inflammatory toxicities, partly due to the activation and secretion of inflammatory cytokines by bystander myeloid cells (BMCs).
Supreet Khanal +5 more
doaj +2 more sources
Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies [PDF]
OncoImmunologyCAR-based cell therapies have shown clinical success in treating various cancers, with CAR T cell therapies entering the clinical route and CAR NK cell therapies being evaluated in early-stage clinical trials.
Katharina Schindler-Wnek +5 more
doaj +2 more sources
CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside [PDF]
Molecular CancerBackground Gastrointestinal (GI) cancers represent a significant health burden worldwide. Their incidence continues to increase, and their management remains a clinical challenge.
Xingwang Zhu +3 more
doaj +2 more sources
Engineering and targeting potential of CAR NK cells in colorectal cancer. [PDF]
Chin Med J (Engl)Abstract Colorectal cancer (CRC), a major global health concern, necessitates innovative treatments. Chimeric antigen receptor (CAR) T cells have shown promises, yet they grapple with challenges. The spotlight pivots to the rising heroes: CAR natural killer (NK) cells, offering advantages such as higher safety profiles, cost ...
Khawar MB, Afzal A, Dong S, Si Y, Sun H.
europepmc +4 more sources
CAR-NK Cells in the Treatment of Solid Tumors [PDF]
International Journal of Molecular Sciences, 2021 CAR-T (chimeric antigen receptor T) cells have emerged as a milestone in the treatment of patients with refractory B-cell neoplasms. However, despite having unprecedented efficacy against hematological malignancies, the treatment is far from flawless.
Ewa Wrona +2 more
openaire +2 more sources